• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型隐球菌抗真菌药物耐药性的实验进化。

Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.

机构信息

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

出版信息

Curr Protoc Microbiol. 2020 Dec;59(1):e116. doi: 10.1002/cpmc.116.

DOI:10.1002/cpmc.116
PMID:32986290
Abstract

Cryptococcus neoformans, an opportunistic yeast-like fungal pathogen, has demonstrated resistance to all major classes of antifungals used to treat cryptococcal meningitis. However, combatting this fungal disease is an ongoing challenge among clinicians due to the evolution of antifungal-resistant strains. The limited availability of clinically approved antifungals has heightened the urgency to investigate the molecular mechanisms underscoring resistance. Studying how a fungal pathogen evolves to an antifungal drug in vitro using experimental evolution provides a simple, yet powerful approach to study the mechanisms of antifungal resistance. Experimental evolution involves the serial passaging of microbial populations under laboratory conditions, such that adaptive mutations can occur and be monitored in real time. This technique plays a key role in investigating the mechanisms of antifungal resistance in C. neoformans, and this can help in developing novel strategies to combat the emergence of resistance. Here, we outline how to make overnight cultures of C. neoformans and how to perform experimental evolution, and we present a spectrophotometric analysis to evaluate the evolution of antifungal resistance. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Growth and sample preparation of Cryptococcus neoformans Basic Protocol 2: Experimental evolution of antifungal resistance Basic Protocol 3: Analyzing the evolution of antifungal resistance Basic Protocol 4: Glycerol stock preparation.

摘要

新型隐球菌是一种机会性酵母样真菌病原体,已表现出对所有用于治疗隐球菌性脑膜炎的主要类别的抗真菌药物的耐药性。然而,由于抗真菌耐药株的出现,对抗这种真菌病一直是临床医生面临的挑战。由于临床批准的抗真菌药物有限,因此迫切需要研究支持耐药性的分子机制。使用实验进化在体外研究真菌病原体对抗真菌药物的进化提供了一种简单而强大的方法来研究抗真菌耐药性的机制。实验进化涉及在实验室条件下对微生物种群进行连续传代,以便适应性突变可以发生并实时监测。该技术在研究新型隐球菌中抗真菌耐药性的机制方面发挥着关键作用,这有助于开发新的策略来对抗耐药性的出现。在这里,我们概述了如何制作新型隐球菌的 overnight cultures 以及如何进行实验进化,并提出了分光光度分析来评估抗真菌耐药性的进化。© 2020 威立公司。基础方案 1:新型隐球菌的生长和样品制备基础方案 2:抗真菌耐药性的实验进化基础方案 3:分析抗真菌耐药性的进化基础方案 4:甘油储备制备。

相似文献

1
Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.新型隐球菌抗真菌药物耐药性的实验进化。
Curr Protoc Microbiol. 2020 Dec;59(1):e116. doi: 10.1002/cpmc.116.
2
Combatting the evolution of antifungal resistance in Cryptococcus neoformans.抗新型隐球菌真菌感染的耐药性演变。
Mol Microbiol. 2020 Nov;114(5):721-734. doi: 10.1111/mmi.14565. Epub 2020 Jul 22.
3
Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.VT-1129对氟康唑最低抑菌浓度较高的新型隐球菌临床分离株的活性。
Med Mycol. 2017 Jun 1;55(4):453-456. doi: 10.1093/mmy/myw089.
4
Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.巴西东南部新型隐球菌/格特隐球菌种复合体临床分离株的分子分型、体外药敏和毒力。
Mycoses. 2020 Dec;63(12):1341-1351. doi: 10.1111/myc.13174. Epub 2020 Sep 30.
5
Evaluation of antifungal activity of cinnamaldehyde against Cryptococcus neoformans var. grubii.评估肉桂醛对新型隐球菌变种的抗真菌活性。
Folia Microbiol (Praha). 2020 Dec;65(6):973-987. doi: 10.1007/s12223-020-00806-4. Epub 2020 Jul 2.
6
Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.新型隐球菌对两性霉素B和氟康唑的抗真菌药敏性。
Indian J Pathol Microbiol. 2006 Apr;49(2):307-8.
7
Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.2011 年至 2017 年间德国获得的新型隐球菌临床分离株的分子分型和体外耐药性。
Int J Med Microbiol. 2019 Sep;309(6):151336. doi: 10.1016/j.ijmm.2019.151336. Epub 2019 Aug 16.
8
Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.在西班牙塞维利亚分离的新型隐球菌和新生隐球菌的分子鉴定、抗真菌耐药性和毒力。
Mycoses. 2017 Jan;60(1):40-50. doi: 10.1111/myc.12543. Epub 2016 Sep 15.
9
A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.一项关于隐球菌属临床分离株中氟康唑耐药性的系统评价。
Mycoses. 2018 May;61(5):290-297. doi: 10.1111/myc.12747. Epub 2018 Feb 14.
10
Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.巴西亚马逊地区新型隐球菌 VNI 和格特隐球菌 VGII 的 Etest、Vitek 2 和临床与实验室标准协会微量肉汤稀释法比较抗真菌药敏分析。
Med Mycol. 2019 Oct 1;57(7):864-873. doi: 10.1093/mmy/myy150.

引用本文的文献

1
Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans.ATP 依赖性解折叠酶 ClpX 的破坏可逆转新生隐球菌的抗真菌耐药性。
Nat Commun. 2025 Jul 7;16(1):6248. doi: 10.1038/s41467-025-61412-x.